Clinical trials: Neoplasm, Oral
Prostate Cancer
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did…
- Trial name
- NRR (NCT00246753)
- Testing
- lapatinib ditosylate
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Primary Liver Cancer
Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
- Trial name
- NCT03166553
- Testing
- Elemene
- Where
- 10 sites in China
- Volunteers
- 150 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Colorectal Neoplasms, Colorectal Adenoma
A Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers
This multicenter, double blinded randomized controlled trial aims to assess the efficacy of a novel oral synbiotic formula (SMT04) in reducing advanced adenoma recurrence and colorectal neoplasia-related bacterial gene markers…
- Conditions
- Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer, Advanced Adenoma
- Trial name
- NCT05592886
- Testing
- SMT04 formula
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 649 people
- Sponsor
- Chinese University of Hong Kong
Oral Squamous Cell Carcinoma, Neck Dissection
Elective vs Therapeutic Neck Dissection in Treatment of Patients With Clinical T1/2N1M0 Oral Squamous Cell Carcinoma
Cervical lymph node metastasis is the most important prognostic factor of oral squamous cell carcinoma (OSCC). Therapeutic neck dissection (I-V region) has always been regarded as the standard scheme of neck surgery for patients…
- Trial name
- NCT05806073
- Testing
- Elective neck dissection, Therapeutic neck dissection
- Volunteers
- 188 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Endometrial Cancer
Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
This is a single centre, single arm, open label, preoperative window of opportunity study. Grade 2 endometrioid endometrial carcinoma patients awaiting surgery will be prospectively recruited to receive a pre-operative progestin…
- Trial name
- MA-EEC (NCT05332483)
- Testing
- Megestrol Acetate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Sunnybrook Health Sciences Centre
Oral Cavity Cancer, Oropharyngeal Cancer
Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients
This four-year, prospective, longitudinal study will evaluate and validate a patient-reported outcome measure, clinician-reported outcome measures, and imaging techniques in assessing characteristics, trajectory, and progression…
- Conditions
- Oral Cavity Cancer, Oropharyngeal Cancer, Lymphedema, Fibrosis
- Trial name
- NCT02412241
- Testing
- LEF measures, Technical measure
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Multiple Myeloma
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter…
- Trial name
- NCT04570631
- Testing
- Eftozanermin alfa, Bortezomib, Dexamethasone
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Stage III Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or…
- Trial name
- NCT01542931
- Testing
- TPF induction chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Multiple Myeloma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- Trial name
- NCT05972135
- Testing
- Teclistamab, Talquetamab, Tocilizumab
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Oral and Esophageal Cancer, Metabolic Syndrome.
The Association Between Areca-nut Chewing Habit and Metabolic Syndrome
The purpose of this study is going to determine the odds ratio of metabolic syndrome (MS), the habit of areca nut chewing, antioxidant, and inflammatory status in oral and esophageal patients.
- Trial name
- NCT02175524
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taichung Veterans General Hospital
Multiple Myeloma
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in…
- Trial name
- NCT01850524
- Testing
- Ixazomib, Dexamethasone, Lenalidomide
- Where
- 147 sites in United States, Belgium and 5 more
- Volunteers
- 705 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Head and Neck Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
- Trial name
- NCT00021424
- Testing
- recombinant fowlpox-TRICOM vaccine
- Where
- United States
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Sarcoma
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
The purpose of this research study is to find out more information such as: to determine the effects of high and low fat foods on the pharmacokinetics (PK) of oral KPT-330 tablets and to compare PK of capsules and tablets in Arms…
- Trial name
- NCT01896505
- Testing
- KCP-330
- Where
- 2 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Karyopharm Therapeutics Inc
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer
Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
Study objective: Cohort 1: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant metastases from breast carcinoma patients and to assess repeatability of the image-based HER2 quantification.
- Conditions
- Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression
- Trial name
- VUBAR (NCT03924466)
- Testing
- 68GaNOTA-Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 55 people
- Sponsor
- Universitair Ziekenhuis Brussel
Heavy Menstrual Bleeding, Uterine Fibroids
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
Uterine Fibroids (UF) are noncancerous (benign) tumors that commonly occur in up to 80% of women of reproductive age. Symptoms can include heavy menstrual bleeding (HMB), low back pain, urinary frequency and urgency…
- Trial name
- REACH (NCT05026502)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- AbbVie
Immunonutrition, Surgical Outcome
Perioperative Supplementation With Immunonutrition and Its Impact on Surgical Outcome and Pain in Oral Cavity or Mandibular Tumours
The aim of this study was to investigate the effect of adding omega 3 and dipeptiven to standard feeding in head and neck patients who will undergo oral cavity tumour resection or mandibular tumour resection (immunonutrrition…
- Conditions
- Immunonutrition, Surgical Outcome, Pain, Oral Cavity
- Trial name
- NCT06339372
- Testing
- Standard feeding, Omega 3 and dipeptiven
- Where
- Egypt
- Volunteers
- 176 people
- Sponsor
- Cairo University
Mesothelioma
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated…
- Trial name
- NCT04857372
- Testing
- IAG933
- Where
- 16 sites in United States, Australia and 9 more
- Volunteers
- 137 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical research study is to learn if the addition of OSI-906 to cetuximab can improve response. The safety of these drugs will also be studied.
- Trial name
- NCT01427205
- Testing
- Cetuximab, OSI-906
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Breast Neoplasms
Study Evaluating HKI-272 in Tumors
The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose (MTD) for HKI-272.
- Trial name
- NCT00146172
- Testing
- neratinib
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- Puma Biotechnology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.